Non-alcoholic fatty liver disease (NAFLD) recurrence after liver transplant (OLT) for non-alcoholic steatohepatitis(NASH)

被引：0

作者：

Kawamura, Norio ^{[1
]}

Nazzal, Mustafa ^{[1
]}

El-Gazzaz, Galal ^{[1
]}

Spaggiari, Mario ^{[1
]}

Fujiki, Masato ^{[1
]}

Diago, Teresa ^{[1
]}

Aucejo, Federico N. ^{[1
]}

Hashimoto, Koji ^{[1
]}

Quintini, Cristiano ^{[1
]}

Winans, Charles ^{[1
]}

Eghtesad, Bijan ^{[1
]}

Miller, Charles M. ^{[1
]}

Fung, John J. ^{[1
]}

Alkhouri, Naim ^{[2
]}

Kelly, Dympna ^{[1
]}

机构：

[1] Cleveland Clin, Transplantat Ctr, Cleveland, OH 44106 USA

[2] Cleveland Clin, Cleveland, OH 44106 USA

来源：

HEPATOLOGY | 2014年 / 60卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

864

引用

页码：617A / 617A

页数：1

共 50 条

[1] Non-alcoholic fatty liver disease (NAFLD). Non-alcoholic steatohepatitis - NASH
Keller, KM
[J]. MONATSSCHRIFT KINDERHEILKUNDE, 2004, 152 (08) : 864 - 869
[2] Recurrence of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Following Liver Transplantation for NASH Cirrhosis
Matsuoka, Lea
Slaughter, James
Campbell, Kathyrn
Kerr, Ashlie
Hamel, Stephanie
Garza, Carissa
Chotai, Pranit
Alexopoulos, Sophoclis
Scanga, Andrew
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 15 - 15
[3] Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment
Bugianesi, E
Marzocchi, R
Villanova, N
Marchesini, G
[J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2004, 18 (06) : 1105 - 1116
[4] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
Jürgen Kurt Rockstroh
[J]. Current HIV/AIDS Reports, 2017, 14 : 47 - 53
[5] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
Rockstroh, Juergen Kurt
[J]. CURRENT HIV/AIDS REPORTS, 2017, 14 (02) : 47 - 53
[6] Non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD) - A growing epidemic
South, K
[J]. GASTROENTEROLOGY NURSING, 2006, 29 (02) : 169 - 169
[7] Non-alcoholic fatty liver disease (NAFLD) after orthotopic liver transplantation (OLT) in patients with cryptogenic cirrhosis (CC) and non-alcoholic steatohepatitis (NASH)
Amaro, R
Montalbano, M
Acosta, RC
Concha, R
Weppler, D
Neff, GW
O'Brien, CB
Molina, EG
Schiff, ER
Tzakis, AG
[J]. GASTROENTEROLOGY, 2001, 120 (05) : A118 - A118
[8] Non-alcoholic Fatty Liver Disease (NAFLD) and non-alcoholic Steatohepatitis (NASH): Pathophysiology and Nutritional Aspects
Schattenberg, Joern M.
[J]. ERNAHRUNGS UMSCHAU, 2015, 62 (02): : M92 - M100
[9] Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course
Cortez-Pinto, H
Camilo, ME
[J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2004, 18 (06) : 1089 - 1104
[10] Linagliptin is an Effective Therapeutic for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)
Klein, Thomas
Mark, Michael
[J]. DIABETES, 2012, 61 : A265 - A266

← 1 2 3 4 5 →